Can I read Pharmacokinetic Interaction Between Mefloquine and Ritonavir in Healthy Volunteers on EtoBox?

Pharmacokinetic Interaction Between Mefloquine and Ritonavir in Healthy Volunteers by Yasmin Khaliq; Keith Gallicano; Christine Tisdale; Germain Carignan; Curtis Cooper; Anne McCarthy is a Medicine article available to read on EtoBox.

What is Pharmacokinetic Interaction Between Mefloquine and Ritonavir in Healthy Volunteers about?

**Aims** To evaluate the pharmacokinetic interaction between ritonavir and mefloquine. **Methods** Healthy volunteers participated in two separate, nonfasted, three‐treatment, three‐period, longitudinal pharmacokinetic studies. Study 1 (12 completed): ritonavir 200 mg twice daily for 7 days, 7 day washout, mefloquine 250 mg once daily for 3 days then once weekly for 4 weeks, ritonavir restarted for 7 days simultaneously with the last mefloquine dose. Study 2 (11 completed): ritonavir 200 mg single dose, mefloquine 250 mg once daily for 3 days then once weekly for 2 weeks, ritonavir single dose repeated 2 days after the last mefloquine dose. Erythromycin breath test (ERMBT) was administered with and without drug treatments in study 2. **Results** __Study 1__: Ritonavir caused less than 7% changes with high precision (90% CIs: −12% to 11%) in overall plasma exposure (AUC(0,168 h)) and peak concentration (__C__~max~) of mefloquine, its two enantiomers, and carboxylic acid metabolite, and in the metabolite/mefloquine and enantiomeric AUC ratios. Mefloquine significantly decreased steady‐state ritonavir plasma AUC(0,12 h) by 31%, __C__~max~ by 36%, and predose levels by 43%, and did not

Who reads Pharmacokinetic Interaction Between Mefloquine and Ritonavir in Healthy Volunteers?

Author

Yasmin Khaliq; Keith Gallicano; Christine Tisdale; Germain Carignan; Curtis Cooper; Anne McCarthy

Publisher

John Wiley and Sons; Wiley (Blackwell Publishing); Blackwell Publishing Inc.; Wiley; Research Square (ISSN 0306-5251)

Published

2001

Language

EN

Field

Medicine (Health Sciences)